GlassScriptPhysician profile
Gregory J Dardas
NPI 1750350096
$5,718.25
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $692 · 2021: $1,377 · 2022: $1,192 · 2023: $1,634 · 2024: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,540.90 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Abbvie INC. | $817.77 | 2021-2024 | Qulipta, Botox, Duopa |
| Novartis Pharmaceuticals Corporation | $418.90 | 2019-2024 | |
| Celgene Corporation | $399.44 | 2020-2023 | Zeposia |
| Ucb, INC. | $244.65 | 2019-2024 | Briviact, Rystiggo |
| Eisai INC. | $230.48 | 2019-2024 | |
| Lilly USA, LLC | $191.55 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $182.08 | 2020-2024 | Ingrezza, Ongentys |
| Genentech USA, INC. | $161.95 | 2019-2023 | Ocrevus, Enspryng |
| Teva Pharmaceuticals USA, INC. | $157.13 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $142.66 | 2019-2022 | |
| Amgen INC. | $130.81 | 2019-2022 | |
| Neurelis, INC. | $130.37 | 2021-2024 | Valtoco |
| Emd Serono, INC. | $109.25 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $99.20 | 2023 | Rexulti, Nuedexta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $96.42 | 2021 | |
| Kyowa Kirin, INC. | $75.07 | 2020-2022 | |
| Genzyme Corporation | $45.73 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $45.08 | 2020-2023 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $42.98 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.08 | 2022 | |
| Corium, LLC | $39.30 | 2022-2023 | Adlarity |
| Jazz Pharmaceuticals INC. | $38.66 | 2023-2024 | Epidiolex |
| Adamas Pharmaceuticals, INC. | $37.50 | 2020-2021 | |
| Avion Pharmaceuticals | $35.86 | 2022-2023 | Dhivy |
| Harmony Biosciences LLC | $34.99 | 2024 | |
| Sumitomo Pharma America, INC. | $31.38 | 2023-2024 | Aptiom |
| Allergan, INC. | $29.41 | 2020 | |
| Tanabe Pharma America, INC. | $26.32 | 2023 | |
| Acorda Therapeutics, INC | $22.15 | 2019 | |
| Pfizer INC. | $21.30 | 2023 | |
| Argenx US, INC. | $20.16 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.70 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.52 | 2019 | |
| Impel Pharmaceuticals INC. | $15.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.62 | 2024 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dardas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.